BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Antithrombotic agents

First Posted Date: 2017-10-17

Last Posted Date: 2019-01-14

Lead Sponsor: Bayer

Target Recruit Count: 14226

Registration Number: NCT03311139

Locations: 🇸🇪
Many locations, Multiple Locations, Sweden

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Phase 1

Completed

Conditions: Cough

Interventions: Drug: BAY1817080
Drug: Matching Placebo

First Posted Date: 2017-10-16

Last Posted Date: 2023-01-26

Lead Sponsor: Bayer

Target Recruit Count: 87

Registration Number: NCT03310645

Locations: 🇬🇧
University Hospital of South Manchester, Manchester, United Kingdom
🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧
Queen's University, Belfast, United Kingdom

and more 4 locations

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Iloprost (Ventavis, BAYQ6256)
Device: Breelib nebulizer

First Posted Date: 2017-09-26

Last Posted Date: 2021-05-26

Lead Sponsor: Bayer

Target Recruit Count: 31

Registration Number: NCT03293407

Locations: 🇩🇪
Many Locations, Multiple Locations, Germany

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Completed

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2017-09-25

Last Posted Date: 2023-06-09

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT03290794

Locations: 🇮🇳
Many Locations, Multiple Locations, India

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Completed

Conditions: Liver Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2017-09-20

Last Posted Date: 2023-06-13

Lead Sponsor: Bayer

Target Recruit Count: 1010

Registration Number: NCT03289273

Locations: 🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
Rutgers University, Newark, New Jersey, United States
🇺🇸
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States

and more 15 locations

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2017-09-15

Last Posted Date: 2020-11-24

Lead Sponsor: Bayer

Target Recruit Count: 1216

Registration Number: NCT03284762

Locations: 🇨🇳
Different facilities, Multiple Locations, Taiwan

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2017-09-11

Last Posted Date: 2018-10-29

Lead Sponsor: Bayer

Target Recruit Count: 2312

Registration Number: NCT03278262

Locations: 🇸🇪
Many locations, Lund, Sweden

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 2

Completed

Conditions: Knee Arthroplasty, Total

Interventions: Drug: BAY1213790
Drug: Enoxaparin
Drug: Apixaban

First Posted Date: 2017-09-08

Last Posted Date: 2020-03-03

Lead Sponsor: Bayer

Target Recruit Count: 813

Registration Number: NCT03276143

Locations: 🇱🇹
Republican Vilnius University Hospital, Vilnius, Lithuania
🇵🇱
Wojewódzki Szpital Zespolony, Kielce, Poland
🇵🇱
Szpital Specjalistyczny im. Rydygiera, Krakow, Poland

and more 51 locations

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Other: Brain MRI
Other: Blood sampling

First Posted Date: 2017-08-31

Last Posted Date: 2019-05-16

Lead Sponsor: Bayer

Target Recruit Count: 261

Registration Number: NCT03269175

Locations: 🇫🇮
Terveystalo Turku, Turku, Finland
🇧🇪
UZ Gent, Gent, Belgium
🇵🇹
Instituto Português de Oncologia Francisco Gentil - Coimbra, Coimbra, Portugal

and more 58 locations

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Vericiguat (BAY1021189)
Drug: Placebo
Drug: Isosorbide mononitrate (ISMN)

First Posted Date: 2017-08-21

Last Posted Date: 2021-12-29

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT03255512

Locations: 🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪
Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany
🇩🇪
SocraTec R&D GmbH, Erfurt, Thüringen, Germany

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy